Version history

{
  "session_id": "sess_SDA-2026-04-21-gap-debate-20260417-033037-c43d12c2_20260421-021018",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "critique",
  "content": "\n\n# Critical Evaluation of C1q-Related Hypotheses\n\n## Hypothesis 1: Glyco-C1q Lectin Bridging\n\n### 1. Strongest Specific Weakness: Unfounded Dual-Domain Assumption\n\nThe hypothesis requires C1q to possess **two functionally distinct binding domains**: one for disease-altered glycans on target surfaces and a separate, unspecified domain engaging microglial lectin receptors (SIGLEC3/CD33, CLEC7A, SIGLEC11). C1q's structure is well-characterized—globular heads mediate target recognition while collagen-like stalks engage complement receptors (CR1, CR2) and FcγRs. **There is no validated lectin-binding domain on C1q**, and the cited SIGLEC/CD33 evidence reflects direct sialic acid recognition by CD33, not a C1q bridge.\n\n### 2. Counter-Evidence and Known Complications\n\n- **CD33 is itself a sialic acid-binding lectin** (SIGLEC family). AD risk variants at CD33 likely affect direct glycan recognition on amyloid-β or neuronal surfaces rather than requiring C1q as an intermediary. FALSIFICATION CONCERN: CD33 knockout phenotypes may be C1q-independent entirely.\n- C1q binding to apoptotic cells involves phosphatidylserine exposure,calcium-dependent phospholipid recognition, and annexin V-inhibitable mechanisms (PMID: 16959611)—not the glycan-specific pattern suggested.\n- SIGLEC11 and SIGLEC3 are predominantly expressed on myeloid cells with well-defined sialic acid recognition motifs; no evidence links their ligand specificity to C1q.\n\n### 3. Pointed Question\n\n**What biochemical evidence—beyond spatial colocalization—demonstrates that C1q physically engages CLEC7A, SIGLEC11, or SIGLEC3/CD33?** SPR, co-immunoprecipitation, or pull-down assays with purified components have not (to my knowledge) validated C1q:SIGLEC interactions. Without this fundamental binding evidence, the ternary complex is speculative scaffolding.\n\n### 4. Confidence Rating: **Weak**\n\n**Justification:** The hypothesis conflates circumstantial associations (C1q presence, AD risk loci, glycan alterations) into a mechanistic model that requires a **structurally unsupported dual-receptor capacity for C1q**. Before pursuing mechanistic studies, the Theorist must demonstrate direct C1q-SIGLEC binding—this is not a refinement issue; it is a foundational falsifiability problem.\n\n---\n\n## Hypothesis 2: ApoE-Isoform C1q Scaffold\n\n### 1. Strongest Specific Weakness: Unvalidated C1q-APOE Binding\n\nThe entire hypothesis rests on C1q binding to lipidated APOE particles, but **no direct binding data is cited or, to my knowledge, exists**. C1q is a pattern-recognition molecule with broad ligand specificity; APOE is a lipid transport protein concentrated at amyloid plaques. The proposal that C1q \"binds lipidated APOE-containing particles\"",
  "tokens_used": "680"
}